Navigation Links
Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
Date:6/4/2008

A. Oclassen, President and Chief Executive Officer of Transcept, commented, "Based on the clinical trial data from our two Phase 3 studies and from additional studies of Intermezzo(R), we believe that our low dose, sublingual formulation of zolpidem, which shows rapid onset in clinical studies, has the potential to offer an entirely new approach to the treatment of patients who wake up in the middle-of-the-night and find it difficult to get back to sleep. We look forward to submitting the Intermezzo(R) NDA this fall."

About Middle of the Night Awakenings

Middle-of-the-night (MOTN) or nocturnal awakenings have been reported to be one of the most common sleep problems, affecting approximately one-third of the adult population. According to a recent epidemiological study ("Nocturnal awakenings and comorbid disorders in the American general population" -- Journal of Psychiatric Research (in press), Maurice M. Ohayon, MD, DSc, PhD.), nocturnal awakenings are the most frequently reported insomnia symptom in the general population, with 35 percent of Americans experiencing awakenings at least three times per week and 23 percent waking up at least once every night. Ninety percent of the MOTN insomnia population report that their pattern of nocturnal awakenings persists for at least six months and 50 percent report such insomnia problems lasting more than 5 years. Currently, there is no approved PRN ("taken as needed") treatment for MOTN awakenings.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose formulation of zolpidem for the treatment of insomnia in patients who awaken in th
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... -- A decade-long JDRF-funded study led by the Institute ... Germany , is providing a deeper understanding of ... type 1 diabetes (T1D), highlighting the importance of pre-diabetes ... "Seroconversion to Multiple Islet Autoantibodies and Risk of Progression ... The Journal of the American Medical Association . ...
(Date:6/19/2013)... 19, 2013  Finesse Solutions, Inc, a manufacturer ... process applications, announced the launch of its new ... culture and fermentation.  The 3L glass vessels are ... Finesse bioreactors and are designed to optimize yield ... fully compatible with all Finesse G3Lab controllers, and ...
(Date:6/19/2013)... 19, 2013  Decision Resources, one of the ... and healthcare issues, finds that, for the treatment ... and European rheumatologists cite a therapy,s induction of ... influences their prescribing decisions. Over 60 percent and ... rank the percentage of patients achieving remission at ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2
... 2011 Cell Therapeutics, Inc. ("CTI" or the "Company") ... results for the first quarter ended March 31, 2011. ... million through two financings, advanced pixantrone into a confirmatory ... Therapeutics Ltd. ("Chroma") to co-develop and market Chroma,s drug ...
... April 26, 2011 BD (Becton, Dickinson and Company) ... technology company, today reported quarterly revenues of $1.922 billion ... representing an increase of 6.8 percent from the prior-year ... percent, despite an unfavorable comparison to the prior year ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 2Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 3Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 4Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 5Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 6BD Announces Results for 2011 Second Fiscal Quarter 2BD Announces Results for 2011 Second Fiscal Quarter 3BD Announces Results for 2011 Second Fiscal Quarter 4BD Announces Results for 2011 Second Fiscal Quarter 5BD Announces Results for 2011 Second Fiscal Quarter 6BD Announces Results for 2011 Second Fiscal Quarter 7BD Announces Results for 2011 Second Fiscal Quarter 8BD Announces Results for 2011 Second Fiscal Quarter 9BD Announces Results for 2011 Second Fiscal Quarter 10BD Announces Results for 2011 Second Fiscal Quarter 11BD Announces Results for 2011 Second Fiscal Quarter 12BD Announces Results for 2011 Second Fiscal Quarter 13BD Announces Results for 2011 Second Fiscal Quarter 14
(Date:6/19/2013)... FL (PRWEB) June 19, 2013 At a ... the positive changes and growth that has occurred over the ... travel club. , Shuman said, "Travel Services has added vendors, ... heights beyond belief. Membership is up, even in the ... meet the demands of members." , Having been in the ...
(Date:6/19/2013)... In 2011, the value of the Serbian ... drugs form the largest sector, accounting for nearly one ... is a significant contributor to the local economy; it ... 50% of the total domestic chemical industry output fall ... and Zdravlje Actavis are key participants in the Serbian ...
(Date:6/19/2013)... the brink of extinction but can we finish the ... a Bristol academic addresses in his new book, published next ... University of Bristol, has produced the first comprehensive history of ... of polio explores the experiences of victims alongside the medical ... , According to a review by The Lancet ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Ultimate Medical ... Telethon, an 11.5-hour broadcast on WFLA News Channel 8. ... collected more than $84 million for All Children's Hospital ... event, themed "30 Years of Miracles," marked the second ... 18 UMA employees worked the phones during the Telethon, ...
(Date:6/19/2013)... Lexington, Mass. (PRWEB) June 19, 2013 ... IT security solutions, today announced that Imprivata OneSign ... KLAS® 2013 Mid-Term Performance Review: Software & Services ... by KLAS laud Imprivata on the superior performance of ... and support, and they indicate that Imprivata is integral ...
Breaking Medicine News(10 mins):Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2Health News:Paralysed with fear: The story of polio 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 3Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3
... , ALLEGAN, Mich., Nov. 9 Perrigo Company (Nasdaq: ... C. Papa will present at the Credit Suisse 18th ... 11:00 p.m. (MT) at the Arizona Biltmore Hotel in ... global healthcare supplier that develops, manufactures and distributes OTC ...
... Simple computerized alerts can help curb the impulse ... study in the August issue of Journal ... clinicians received computerized alerts, which compared medication brands, ... heavily marketed sleep medications to comparable generic equivalents. ...
... Research carried out among thousands of people has shown ... mass, leading to osteoporosis and fractures. This was ... head of the Brain and Behavior Laboratory, and Prof. Itai ... the relationship between depression and bone loss is particularly strong ...
... the clock 8 years, research shows , MONDAY, Nov. 9 ... improves so much that most feel eight years younger, a new ... everyone except a small minority -- only 2 percent -- who ... "The results really say three things: That work puts an extra ...
... announced today the acquisition of App Tech Global, Inc., which ... Natural Nutrition,s name will be changed to App Tech, Corp. ... of App Tech Global, Inc. , App Tech is developing ... App Tech is focused on multi platform apps designed ...
... China, Nov. 9 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... leading pharmaceutical company,specializing in the development, manufacturing, and ... today announced an agreement,to acquire the manufacturing license ... Ltd. ("Tianda"). The acquisition of the,manufacturing license will ...
Cached Medicine News:Health News:Computerized support keeps prominence of name brand drugs at bay 2Health News:Connection between depression and osteoporosis detailed by Hebrew University researchers 2Health News:Retirement Brings Most a Big Health Boost 2Health News:Retirement Brings Most a Big Health Boost 3Health News:Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 2
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
10 L, Bulk Recommended for 5 and 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 L tip additionally combats contamination by keeping your pipettor out of 1.5 L and 2.0 L tubes....
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Medicine Products: